Clinical study on gefinitib in the treatment of non -small -cell lung cancer harboring mutations of epidermal growth factor receptor
10.13699/j.cnki.1001-6821.2015.16.012
- VernacularTitle:吉非替尼治疗表皮生长因子受体突变晚期非小细胞肺癌的临床研究
- Author:
Yong-Xian GUI
1
;
Guo-Fang TIAN
Author Information
1. 新乡市中心医院 肿瘤内科
- Keywords:
gefinitib;
docetaxel;
cisplatin;
clinical effect;
survival
- From:
The Chinese Journal of Clinical Pharmacology
2015;(16):1597-1599
- CountryChina
- Language:Chinese
-
Abstract:
Objective To discussed clinical efficacy and safety of gefinitib compared with chemotherapy in the treatment of non-small-cell lung cancer ( NSCLC) harboring mutations of epidermal growth factor receptor( EGFR) .Methods A total of 43 NSCLC patients harboring mutations of EGFR were included in this study and divided into treatment group ( n=22 ) and control group ( n=21 ) .Patients in the treatment group received gefinitib 250 mg? d-1 orally, and those in control group were administered with docetaxe 60 mg? m-2 plus cisplatin 80 mg? m-2 intravenously until progression or unbearable adverse reactions.The data of objective response rate, progression free survival and adverse reactions were compared between the two groups.Results The objective response rate and disease control rate was 59.1%, 90.9%in treatment group and 33.3%, 76.2% in control group, respectively.The objective response rate was significantly higher in treatment group compared to that in control group ( P<0.05 ) .The median progression free survival time was 11.95 months and 6.90 months in treatment group and control group, respectively, which showed that the survial time in the treatment group was much longer (HR=0.49, 95%CI:0.24-1.01, P<0.05).The main grade 3-4 adverse reactions were rash and diarrhea in treatment group and leucocytopenia and anemia in control group.The incidence rate of leucocytopenia was significantly higher in control group than that in treatment group (P<0.05).Conclusion Gefinitib treatment for NSCLC harbouring mutations of EGFR has longer progression free survival and better efficacy.
